AU2015279571A1 - Hepcidin and mini-hepcidin analogues and uses therof - Google Patents

Hepcidin and mini-hepcidin analogues and uses therof Download PDF

Info

Publication number
AU2015279571A1
AU2015279571A1 AU2015279571A AU2015279571A AU2015279571A1 AU 2015279571 A1 AU2015279571 A1 AU 2015279571A1 AU 2015279571 A AU2015279571 A AU 2015279571A AU 2015279571 A AU2015279571 A AU 2015279571A AU 2015279571 A1 AU2015279571 A1 AU 2015279571A1
Authority
AU
Australia
Prior art keywords
absent
lys
ala
arg
cys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015279571A
Other languages
English (en)
Inventor
Gregory Thomas Bourne
Brian Troy FREDERICK
Mark Leslie Smythe
Simone VINK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protagonist Therapeutics Inc
Original Assignee
Protagonist Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protagonist Therapeutics Inc filed Critical Protagonist Therapeutics Inc
Publication of AU2015279571A1 publication Critical patent/AU2015279571A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2015279571A 2014-06-27 2015-06-29 Hepcidin and mini-hepcidin analogues and uses therof Abandoned AU2015279571A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462018382P 2014-06-27 2014-06-27
US62/018,382 2014-06-27
PCT/US2015/038370 WO2015200916A2 (en) 2014-06-27 2015-06-29 Hepcidin and mini-hepcidin analogues and uses therof

Publications (1)

Publication Number Publication Date
AU2015279571A1 true AU2015279571A1 (en) 2017-02-02

Family

ID=54938965

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015279571A Abandoned AU2015279571A1 (en) 2014-06-27 2015-06-29 Hepcidin and mini-hepcidin analogues and uses therof

Country Status (10)

Country Link
US (2) US20170313754A1 (enExample)
EP (1) EP3161164A4 (enExample)
JP (1) JP2017523959A (enExample)
KR (1) KR20170043509A (enExample)
CN (1) CN107075574A (enExample)
AU (1) AU2015279571A1 (enExample)
CA (1) CA2953721A1 (enExample)
IL (1) IL249692A0 (enExample)
SG (1) SG11201610799WA (enExample)
WO (1) WO2015200916A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60231804D1 (de) 2001-05-25 2009-05-14 Inst Nat Sante Rech Med Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
AU2014232954B2 (en) 2013-03-15 2018-08-09 Protagonist Therapeutics, Inc. Hepcidin analogues and uses therof
US11504346B2 (en) 2013-11-03 2022-11-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Redox-activated pro-chelators
US12383518B2 (en) 2013-11-03 2025-08-12 Arizona Board Of Regents On Behalf Of The University Of Arizona Disulfide-masked pro-chelator compositions and methods of use
ES2890600T3 (es) 2014-05-16 2022-01-20 Protagonist Therapeutics Inc Péptidos de tioéter antagonistas de integrina alfa4beta7
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
US10301371B2 (en) 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
CA2962642A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. Novel .alpha.4.beta.7 peptide monomer and dimer antagonists
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
BR112018013833A2 (pt) * 2016-01-08 2018-12-11 La Jolla Pharmaceutical Company métodos de administração de hepcidina
US10407468B2 (en) 2016-03-23 2019-09-10 Protagonist Therapeutics, Inc. Methods for synthesizing α4β7 peptide antagonists
US20180099023A1 (en) * 2016-09-06 2018-04-12 La Jolla Pharmaceutical Company Methods of treating iron overload
MX2019007236A (es) * 2016-12-19 2019-09-06 La Jolla Pharma Co Metodos de administracion de hepcidina.
WO2018128828A1 (en) 2016-12-23 2018-07-12 Bayer Healthcare Llc Novel hepcidin mimetics and uses thereof
US20200170971A1 (en) * 2017-07-18 2020-06-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Disulfide-masked pro-chelator compositions and methods of use
EP3681900A4 (en) 2017-09-11 2021-09-08 Protagonist Therapeutics, Inc. OPIOID AGONIST PEPTIDES AND THEIR USES
EP4501952A3 (en) * 2018-02-08 2025-04-16 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
EP3894416B1 (en) 2018-12-13 2022-11-09 Global Blood Therapeutics, Inc. Ferroportin inhibitors and methods of use
EP3966226B1 (en) 2019-05-07 2025-12-24 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
CN116082455A (zh) 2019-07-10 2023-05-09 领导医疗有限公司 白细胞介素-23受体的肽抑制剂及其用于治疗炎症性疾病的用途
US20220372099A1 (en) * 2019-09-03 2022-11-24 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
EP4041243A4 (en) * 2019-09-27 2023-10-18 Disc Medicine, Inc. METHODS OF TREATMENT OF ANEMIA OF CHRONIC DISEASE
KR20220088699A (ko) * 2019-09-27 2022-06-28 디스크 메디슨, 인크. 골수섬유증 및 관련 상태의 치료 방법
WO2021146454A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
MA58373B1 (fr) 2020-01-15 2025-07-31 Janssen Biotech, Inc. Inhibiteurs peptidiques du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires
JP7742850B2 (ja) 2020-04-28 2025-09-22 グローバル ブラッド セラピューティクス インコーポレイテッド フェロポルチン阻害剤としてのシクロアルキルピリミジン
EP4143197A1 (en) 2020-04-28 2023-03-08 Global Blood Therapeutics, Inc. Thieno pyrimidines as ferroportin inhibitors
EP4142732A1 (en) 2020-04-28 2023-03-08 Global Blood Therapeutics, Inc. Methods of use for pyrimidines as ferroportin inhibitors
JP2023528223A (ja) 2020-05-13 2023-07-04 ディスク・メディシン・インコーポレイテッド 骨髄線維症を処置するための抗ヘモジュベリン（ｈｊｖ）抗体
CN111560051B (zh) * 2020-05-26 2022-11-25 大连工业大学 一种具有促铁吸收活性的虾源九肽及其应用
CN115997130A (zh) * 2020-07-02 2023-04-21 坦佩雷大学注册基金会 基于肾素的铁调素分析
KR20230053615A (ko) * 2020-07-28 2023-04-21 프로타고니스트 테라퓨틱스, 인코포레이티드 접합된 헵시딘 모방체
CN114252627A (zh) * 2020-09-24 2022-03-29 首都医科大学附属北京世纪坛医院 尿液铁调素及其多肽片段在过敏性疾病中的应用
MX2023005994A (es) 2020-11-20 2023-08-11 Janssen Pharmaceutica Nv Composiciones de inhibidores peptidicos del receptor de interleucina-23.
EP4314017A4 (en) * 2021-04-01 2025-09-10 Protagonist Therapeutics Inc CONJUGATED HEPCIDIN MIMETICS
CA3220871A1 (en) * 2021-06-14 2022-12-22 Protagonist Therapeutics, Inc. Hepcidin mimetics for treatment of hereditary hemochromatosis
EP4370146A4 (en) 2021-07-14 2025-05-21 Janssen Biotech, Inc. Lipidated peptide inhibitors of the interleukin-23 receptor
CN115703826B (zh) * 2021-08-03 2025-05-06 浙江大学 铁调素改造体及其应用
WO2024059264A1 (en) * 2022-09-15 2024-03-21 Migal Galilee Research Institute Ltd Site-specific activation of regulatory t cells
WO2025224128A1 (en) 2024-04-24 2025-10-30 Institut National de la Santé et de la Recherche Médicale Methods of treatment of iron overload associated diseases by administration hepcidin locally in the gut

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010517529A (ja) * 2007-02-02 2010-05-27 アムジエン・インコーポレーテツド ヘプシジン及びヘプシジン抗体
CN101358201A (zh) * 2007-07-31 2009-02-04 钱忠明 重组人铁调素腺病毒、其制备方法及应用
CN101307085B (zh) * 2007-08-01 2012-06-13 香港理工大学深圳研究院 抑制铁调素调节蛋白的siRNA、重组慢病毒及其应用
GR1006896B (el) * 2007-08-24 2010-07-20 Ελληνικο Ινστιτουτο Παστερ, Μεθοδος παραγωγης μιας πεπτιδικης ορμονης
WO2010065815A2 (en) * 2008-12-05 2010-06-10 The Regents Of The University Of California Mini-hepcidin peptides and methods of using thereof
US20130236977A1 (en) * 2010-05-24 2013-09-12 Children's Medical Center Corporation Compositions and methods for plasma peptide analysis
AU2012327226C1 (en) * 2011-12-09 2017-03-02 The Regents Of The University Of California Modified mini-hepcidin peptides and methods of using thereof
AU2014232954B2 (en) * 2013-03-15 2018-08-09 Protagonist Therapeutics, Inc. Hepcidin analogues and uses therof

Also Published As

Publication number Publication date
CA2953721A1 (en) 2015-12-30
CN107075574A (zh) 2017-08-18
JP2017523959A (ja) 2017-08-24
SG11201610799WA (en) 2017-01-27
EP3161164A2 (en) 2017-05-03
WO2015200916A2 (en) 2015-12-30
IL249692A0 (en) 2017-02-28
US20170313754A1 (en) 2017-11-02
KR20170043509A (ko) 2017-04-21
EP3161164A4 (en) 2018-04-25
US20200017566A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
US12269856B2 (en) Hepcidin analogues and uses thereof
US20200017566A1 (en) Hepcidin and mini-hepcidin analogues and uses therof
US11472842B2 (en) Analogues of hepcidin mimetics with improved in vivo half lives
US12234300B2 (en) Conjugated hepcidin mimetics
WO2022026633A1 (en) Conjugated hepcidin mimetics
WO2022212698A1 (en) Conjugated hepcidin mimetics
HK1220112B (en) Hepcidin analogues and uses therof

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period